Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1978 1
1980 1
1981 1
1983 1
1989 2
1990 1
1991 2
1995 1
1997 2
1998 1
1999 5
2000 1
2001 1
2002 3
2003 1
2004 7
2005 4
2006 3
2007 7
2008 10
2009 8
2010 10
2011 9
2012 10
2013 10
2014 7
2015 9
2016 8
2017 8
2018 8
2019 10
2020 6
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Lancet Diabetes Endocrinol. 2019. PMID: 31422062
We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). …
We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, …
Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B. Zhou Z, et al. Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009. Stroke. 2019. PMID: 30591006 Free PMC article. Clinical Trial.
Background and Purpose- This study reports the detailed effects of canagliflozin on stroke, stroke subtypes, and vascular outcomes in participants with and without cerebrovascular disease (stroke or transient ischemic attack) at baseline from the CANVAS (Canagliflozin Cardiovascu …
Background and Purpose- This study reports the detailed effects of canagliflozin on stroke, stroke subtypes, and vascular outcomes in partic …
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. Inzucchi SE, et al. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4. Diabetes Care. 2018. PMID: 29203583 Clinical Trial.
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the H …
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to C …
Diabetes with early kidney involvement may shorten life expectancy by 16 years.
Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, Wen C, Chen CH, Kao CW, Tsao CK, Wu X. Wen CP, et al. Kidney Int. 2017 Aug;92(2):388-396. doi: 10.1016/j.kint.2017.01.030. Epub 2017 Jun 1. Kidney Int. 2017. PMID: 28577854
The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related groups were iden …
The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed fr …
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. MacDonald MR, et al. Eur Heart J. 2008 Jun;29(11):1377-85. doi: 10.1093/eurheartj/ehn153. Epub 2008 Apr 14. Eur Heart J. 2008. PMID: 18413309 Clinical Trial.
METHODS AND RESULTS: We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF. ...
METHODS AND RESULTS: We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHA …
Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014.
Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Benoit SR, et al. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365. doi: 10.15585/mmwr.mm6712a3. MMWR Morb Mortal Wkly Rep. 2018. PMID: 29596400 Free PMC article.
Better understanding the causes of this increasing trend in DKA hospitalizations and decreasing trend in in-hospital case-fatality through further exploration using multiple data sources will facilitate the targeting of prevention efforts....
Better understanding the causes of this increasing trend in DKA hospitalizations and decreasing trend in in-hospital case-fatality through f …
Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Morrish NJ, et al. Diabetologia. 2001 Sep;44 Suppl 2:S14-21. doi: 10.1007/pl00002934. Diabetologia. 2001. PMID: 11587045
The low excess mortality in the Japanese cohort could have implications for the possible reduction of the burden of mortality associated with diabetes in other parts of the world....
The low excess mortality in the Japanese cohort could have implications for the possible reduction of the burden of mortality associa …
Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer.
Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Armstrong DG, et al. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2. J Foot Ankle Res. 2020. PMID: 32209136 Free PMC article.
While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be directed at primary prevention as well as those for patients in diabetic foot ulcer remission to maximize ulcer-free, hospital-free and activity-rich days....
While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be directed at primary prevention
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis.
Shao H, Lin J, Zhuo X, Rolka DB, Gregg EW, Zhang P. Shao H, et al. Diabetes Care. 2019 Nov;42(11):2136-2142. doi: 10.2337/dc19-0381. Epub 2019 Sep 17. Diabetes Care. 2019. PMID: 31530661
RESEARCH DESIGN AND METHODS: We used data from the 2011-2016 National Health and Nutrition Examination Survey (NHANES) to generate nationally representative subgroups of older individuals with diabetes with various health states. We used the Centers for Disease Control and Pre
RESEARCH DESIGN AND METHODS: We used data from the 2011-2016 National Health and Nutrition Examination Survey (NHANES) to generate nationall …
140 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page